Cite

HARVARD Citation

    Wan, R. et al. (2021). Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind study. EClinicalMedicine. p. . [Online]. 
  
Back to record